1. 23andMe and GSK in joint effort to mine customer DNA data with an eye to drug development — Biogen earnings — Speculation on JNJ opioid settlement total — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Opdivo

Discussion in 'Bristol-Myers Squibb' started by anonymous, Jun 18, 2019 at 10:16 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Keytruda has kicked your ass and continues to do it. What a screw up BMY has done with Opdivo. Had the market, got greedy, and LOST. Celgene just see what Wall Street thinks about this CEO decision. These analysts actually know what they are talking about while BMY so called leaders, the same group who screwed up Opdivo, are the same leaders who embellished this debacle
     

  2. anonymous

    anonymous Guest

    It is unfortunate that the above pollster hit the nail on the head. Cafario clueless
     
  3. anonymous

    anonymous Guest

    I have to agree with these posts. Take a look at BMY stock since the Opdivo screwed up studies as well as the Celgene takeover. Worst performing stock in the pharmaceutical sector. This is the reality of the decisions which have been made. Wall Street has nothing against BMY just the decisions that have been made and continue to be made. Take a look at BMY stock over the last 5 years. Sad commentary but created by BMY. No one else to blame!,
     
  4. anonymous

    anonymous Guest

    Interesting perspective from outsider.
    5 years ago today BMS stock was 47.79....today is closed at 48.21.
    It did have a peak hi of 76.00 or so July 2016 but since then its pulled back 30%...
    ….wow.
     
  5. anonymous

    anonymous Guest

    The pollster is correct that BMY stock has been one of the worst performers and the design of the study for Opdivo, all comers as opposed to pd1 expressers, cost Opdivo its perch and since Merck’s Keytruda has killed it vs Opdivo Yes I am an outsider and realize this Celgene deal will go a long way to killing any chance of significant growth. As I stated look what Wall Street says. They do not care if they buy Merck or BMY stock. Merck stock is killing it BMY stock has been and remains one of the worst perfemers
     
  6. anonymous

    anonymous Guest

    This pollster is spot on. Opdivo had a significant lead on Keytruda before the greed of BMY anyone with cancer regardless of pd1 expression got in the way. BMY were pigs trying to get all the market. Keytruda carefully selected its patients got the desired result and now Opdivo will never compete. Cafario being a hematology oncology doc should have known better. The Celgene deal is seen by Wall Street as a bad decision. WOW! What a leadership team.
     
  7. anonymous

    anonymous Guest

    Opdivo is done. BMY truly screwed up. The designer of their trials was an jdiot. No one would have ever known Keytruda is better than Opdivo if BMY would not have given Merck the opening
     
  8. anonymous

    anonymous Guest

    Opdivo is done? LOL. Love when people who don't understand the science try to jump in. Will it ever take the lead in NSCLC, snowballs chance in hell.

    Will it continue to lead where it already is, and diversify? Of course it will.
     
  9. anonymous

    anonymous Guest

    Just keep drinking the Kool Aid
     
  10. anonymous

    anonymous Guest

    Paired by science? Proven by time? Seriously? Every time I tell doctors that we have some more hopeful indications in different tumors down the line with the OY combination they roll their eyes and shake their heads. One doctor just recently told me it would be nice if your company came up with smarter combinations rather than always pairing your own drugs together. I just don’t think BMS leaders really understand how toxic Yervoy is. Two chief scientific officers gone and yet still no one outside of research and development has been held accountable. Are we ever going to look at the CEO?
     
  11. anonymous

    anonymous Guest

    Trials, as one pollster said greed, Keytruda made all the right moves, drugs are more similar than different, perception now that Keytruda is better, BMY will not change that. Keytruda will continue to grow as it does now at the expense of Opdivo. BMY had the market and blew it. Facts not kool aid.
     
  12. anonymous

    anonymous Guest

    Thank you Cafario for screwing up the rise of Opdivo. Opdivo and Celgene. Anthony Hooper would not have screwed up such a great drug. BMS is and will continue to be the dog on Wall Street
     
  13. anonymous

    anonymous Guest

    More fails from Opdivo.

    As a Celgene employee. I'm wondering what Bruce Willis wanna bee got us into by selling us.
     
  14. anonymous

    anonymous Guest

    Look at the shares of BMY today. Thank you Cafario
     
  15. anonymous

    anonymous Guest

    And the shares of Celgene OUCH!
     
  16. anonymous

    anonymous Guest

    Now Cafario with your great Celgene deal has to sell a 2 billion dollar product to get your ridiculous deal to pass. Wall Street knew you had no clue with this deal and all the people who fought the buyout were right. Opdivo another failed trial. Bring back Tony Hooper. You are mindless Cafario. What other great deals have you done?
     
  17. anonymous

    anonymous Guest

    Cafario was the great leader who sold off the Farxiga team I believe. Farxiga just had some tremendous data presented at the ADA meeting. Opdivo has lost tremendous share to Merck due to the trials on Opdivo which failed. As a hematologist oncologist Cafario should have known that a drug which acts on PD1 will not work in non expressers of PD1. You were cocky and lost
     
  18. anonymous

    anonymous Guest

    This is true unfortunately. Cafario has continued to make bad decisions and has assured BMS will be in the shitter on Wall Street. Look at what happened today. Opdivo flop and sell off a 2 billion dollar drug to finalize the Celgene deal which is looked upon as a terrible investment. These Wall Street warriors actually do know what is going on when deals are made. They do not have an agenda and just look at the facts. Look at BMS stock today. Worst day of any major pharmaceutical company this year. In a year where stocks are flying BMS is down for the year. Great job Cafario. And it is true Farxiga was sold off on Caforio’s watch. You are terrible. Resign!
     
  19. anonymous

    anonymous Guest

    Get rid of your moron oncology pods. They are the biggest joke in pharma.
     
  20. anonymous

    anonymous Guest

    You actually saw a doctor? Or was it one of your imaginary call reports?